

## Author Acknowledgments

RAPS and the lead editors, Anu Gaur and Karen Zhou, thank the following subject matter experts for sharing their experience and knowledge and volunteering their time to contribute to this first edition of Postmarket Requirements for Medical Devices: A Practical Guide.

**Rajaram Balasubramanian,**  
RAC-US, RAC-EU, PMP

Director, Regulatory Affairs  
and Quality Assurance,  
TIMEA  
Elekta Medical Systems India  
Pvt Ltd  
India  
*Chapters 9 and 10*

**Karen Fan, MSc, RAC, Peng,**  
PMP

EU MDR Consultant  
Johnson & Johnson Surgical  
Vision Inc.  
Canada  
*Chapter 3*

**Anu Gaur, PhD, MBA,**  
MSRA, RAC-US,  
RAC-Global

President  
SYNERGY Global  
Regulatory Affairs  
Consultancy, Inc.  
US  
*Lead Editor, Preface, and  
Chapter 1*

**Michelle Jump, MSc, RAC**

CEO  
MedSec  
US  
*Chapter 18*

**Barbara Leukers, Dipl.**  
Chem (FH), RAC

Consultant  
Leukers-Consulting  
Germany  
*Chapter 8*

**Shikha Malik, MPharm, MS,**  
RAC-Devices

Senior Regulatory Affairs  
Specialist  
Medtronic  
US  
*Chapter 2*

**Cathy Matthews, MSc**

Regulatory Affairs Specialist  
Edwards Lifesciences Canada  
Inc.  
Canada  
*Chapter 4*

**Sharon Perez, PhD**

Vice President, Global  
Medical Safety  
Novocure  
US  
*Chapters 11 through 17*

**Sharad Mi Shukla, RAC-US,**  
RAC EU

Director Regulatory Affairs  
MedTech  
Johnson & Johnson  
Singapore  
*Chapters 9 and 10*

**Julia Stindl, PhD**

Head of Global Post-Market  
Safety  
Novocure  
Germany  
Chapters 11, 12, 13, 16, and 17

**Ana Subramanian, MSc,**  
PhD, RAC

Canada  
*Chapters 6 and 8*

**Echo Yu, MSc, RAC-Global**

QA/RA Director  
Sinocare Meditech, Inc.  
Canada  
*Chapter 7*

**Karen Zhou, JD, MS, RAC-**  
Devices, RAC-Global

Faculty, MS Regulatory  
Affairs Program  
Northeastern University  
Canada  
*Lead Editor, Preface, and  
Chapter 5*



SECTION

**I**

North America:  
United States  
and Canada

**Section I: North America: United States and Canada**

Chapter 1: Postmarket Compliance and Product Changes: US

# 1

## Postmarket Compliance and Product Changes: US

*By Anu Gaur, PhD, MBA, MSRA, RAC-US, RAC-Global*

### Introduction

In the US, the legislative requirements set forth in Section 522 of the Food, Drug, and Cosmetics Act (FD&C Act) mandate postmarket surveillance for medium (Class II) and high-risk (Class III) medical devices. The US Food and Drug Administration's (FDA) Center for Devices and Radiological Health (CDRH) is responsible for protecting and promoting the public health by ensuring timely and continued access to safe, effective, and high-quality medical devices and safe radiation-emitting products for healthcare.<sup>1</sup>

In general, postmarket surveillance refers to the monitoring process for legally marketed medical products, which constitutes an active, systematic, and scientifically valid collection of data related to their intended clinical use, data analysis, and its interpretation for safety and performance outcomes. In this process, the monitoring of postmarket product-related adverse events (AEs), including their frequency, occurrence, and severity, applies to any product-related safety concerns, public health impact, and justification for a medical device's safety, performance, and efficacy.

FDA requirements for medical device reporting were enacted in December 1984. However, the US Congress first granted FDA

the authority to enforce and require certain medical device manufacturers to conduct postmarket surveillance, per Section 522 of the Safe Medical Devices Act (SMDA) of 1990. The SMDA further provided FDA with two additional post-market activities, including:

1. Postmarket surveillance for the monitoring of products after their market clearance
2. Device tracking for maintaining traceability of certain devices to the user level

Section 212 of the Food and Drug Modernization Act (FDAMA) of 1997 further amended the Section 522 in part to stipulate that the postmarket surveillance may be required by order for any Class II or Class III device the failure of which would be reasonably likely to have serious adverse health consequences, which is intended to be implanted in the human body for more than one year, or which is a life-sustaining or life-supporting device used outside a device user facility.<sup>2-4</sup>

Under Section 212 of FDAMA, FDA is authorized to require a prospective surveillance period of up to 36 months, unless FDA determines a longer period is necessary, and there is a mutual agreement between FDA and the